Rate of change in maximum

Adult Aged Aged, 80 and over Brain Neoplasms / diagnostic imaging Cell Transformation, Neoplastic / metabolism Dihydroxyphenylalanine / analogs & derivatives Female Glioma / diagnostic imaging Humans Magnetic Resonance Imaging Male Middle Aged Positron-Emission Tomography Sensitivity and Specificity Survival Analysis Tumor Burden Young Adult
18F-FDOPA PET Biomarker Low grade glioma MRI

Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 24 10 2019
accepted: 18 01 2020
pubmed: 26 1 2020
medline: 21 11 2020
entrez: 26 1 2020
Statut: ppublish

Résumé

To examine whether the rate of change in maximum 27 LGG patients with ≥ 2 A GLM using patient age, treatment, the rate of change in FLAIR and The change in maximum normalized

Identifiants

DOI: 10.1007/s11060-020-03407-w PMID: 31981013 PMC: PMC7080591
pubmed: 31981013
doi: 10.1007/s11060-020-03407-w
pii: 10.1007/s11060-020-03407-w
pmc: PMC7080591
mid: NIHMS1551516
doi:

Substances chimiques

fluorodopa F 18 2C598205QX
Dihydroxyphenylalanine 63-84-3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-145

Subventions

Organisme : NIH HHS
ID : 1P50CA211015-01A1
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : American Brain Tumor Association
ID : ARC1700002
Organisme : NIH HHS
ID : 1R21CA223757-01
Pays : United States
Organisme : American Cancer Society
ID : RSG-15-003-01-CCE
Organisme : NCI NIH HHS
ID : R21 CA223757
Pays : United States
Organisme : EPA
ID : EP-C-15-003
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom

Références

J Nucl Med. 2012 Nov;53(11):1709-15
pubmed: 23055534
Neuro Oncol. 2017 Jan;19(1):89-98
pubmed: 27580889
Nucl Med Biol. 1996 Apr;23(3):189-99
pubmed: 8782226
Radiology. 2014 Apr;271(1):200-10
pubmed: 24475840
J Nucl Med. 2009 Dec;50(12):1962-8
pubmed: 19910435
J Clin Oncol. 2012 Sep 1;30(25):3065-70
pubmed: 22851558
Lancet Oncol. 2011 Jun;12(6):583-93
pubmed: 21474379
AJNR Am J Neuroradiol. 2013 May;34(5):944-50, S1-11
pubmed: 23124638
J Nucl Med. 2012 Feb;53(2):207-14
pubmed: 22302961
Am J Clin Oncol. 2003 Jun;26(3):e60-6
pubmed: 12796617
Nucl Med Biol. 2015 Oct;42(10):788-95
pubmed: 26162582
J Nucl Med. 2006 Jun;47(6):904-11
pubmed: 16741298
J Neurooncol. 2018 Sep;139(2):399-409
pubmed: 29679199
Neurology. 1991 May;41(5 Suppl 2):24-7; discussion 28
pubmed: 1904139
Neurosurg Focus. 2015 Jan;38(1):E6
pubmed: 25552286
Clin Nucl Med. 2017 Apr;42(4):250-257
pubmed: 28114224
Med Phys. 1998 Oct;25(10):2046-53
pubmed: 9800714
J Nucl Med. 2010 Oct;51(10):1532-8
pubmed: 20847166
N Engl J Med. 2016 Apr 7;374(14):1344-55
pubmed: 27050206
Anticancer Res. 2015 Sep;35(9):5117-22
pubmed: 26254416
J Nucl Med. 2013 Feb;54(2):229-35
pubmed: 23232275
Lancet Neurol. 2003 Jul;2(7):395-403
pubmed: 12849117
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1049-58
pubmed: 21570201
Neuro Oncol. 2012 Aug;14(8):1079-89
pubmed: 22711609
Lancet Neurol. 2006 Jan;5(1):75-86
pubmed: 16361025
J Nucl Med. 2012 Jan;53(1):29-36
pubmed: 22159180
Clin Nucl Med. 2011 Oct;36(10):841-7
pubmed: 21892031
Med Pediatr Oncol. 1993;21(4):301-6
pubmed: 8469227
Int J Rad Appl Instrum A. 1992 Aug;43(8):989-96
pubmed: 1330984
J Nucl Med. 2004 Sep;45(9):1431-4
pubmed: 15347707
J Neurosurg. 2001 Nov;95(5):735-45
pubmed: 11702861
IEEE Trans Med Imaging. 2001 May;20(5):365-75
pubmed: 11403196
J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii31-6
pubmed: 15146037
Eur J Nucl Med. 2000 May;27(5):542-9
pubmed: 10853810
Neuro Oncol. 2014 Mar;16(3):414-20
pubmed: 24305712
N Engl J Med. 2016 Aug 4;375(5):490-1
pubmed: 27518677
Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1933-42
pubmed: 17763848

Auteurs

Talia C Oughourlian (TC)

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Neuroscience Interdepartmental Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Jingwen Yao (J)

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Department of Bioengineering, Henry Samueli School of Engineering, University of California Los Angeles, Los Angeles, CA, USA.

Jacob Schlossman (J)

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Neuroscience Interdepartmental Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Catalina Raymond (C)

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Matthew Ji (M)

UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Hiroyuki Tatekawa (H)

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Noriko Salamon (N)

Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Whitney B Pope (WB)

Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Johannes Czernin (J)

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Phioanh L Nghiemphu (PL)

UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Albert Lai (A)

UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Timothy F Cloughesy (TF)

UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

Benjamin M Ellingson (BM)

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. bellingson@mednet.ucla.edu.
Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. bellingson@mednet.ucla.edu.
Neuroscience Interdepartmental Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. bellingson@mednet.ucla.edu.
Department of Bioengineering, Henry Samueli School of Engineering, University of California Los Angeles, Los Angeles, CA, USA. bellingson@mednet.ucla.edu.
UCLA Brain Tumor Imaging Laboratory, Departments of Radiological Sciences and Psychiatry, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA. bellingson@mednet.ucla.edu.
ORCID: 0000-0002-2764-6640

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Rate of change in maximum
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Rate of change in maximum
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Rate of change in maximum
questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › Rate of change in maximum
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Carcinogenèse › Transformation cellulaire néoplasique › Rate of change in maximum
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés cycliques › Acides aminés aromatiques › Tyrosine › Dopa › Rate of change in maximum
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Rate of change in maximum
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Rate of change in maximum
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Rate of change in maximum
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Rate of change in maximum
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Rate of change in maximum
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Sensibilité et spécificité › Rate of change in maximum
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Rate of change in maximum
questionsmedicales.fr › Techniques d'investigation › Charge tumorale › Rate of change in maximum
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Rate of change in maximum